This study involves people living with HIV who are on medication to control the virus. It aims to explore how a new vaccine combination can help the body produce antibodies (special proteins that fight germs) against HIV. The study is in its first phase, meaning it's early in testing and involves multiple centers working together. Participants will receive a vaccine designed to stimulate their immune system to combat HIV more effectively. The study will look at how well the vaccine works in producing specific antibodies and its effect on the virus.

• Participants must be aged 18-55, living with HIV, and on stable HIV medication.
• They should be in good health and willing to follow study procedures, including using contraception if needed.
• The study will involve multiple clinic visits and follow-ups, and participation can last up to 64 weeks.

Before joining, potential participants will need to go through a screening process to ensure they meet all the requirements. This study offers a chance to contribute to HIV research that might lead to better treatment options in the future.